Adaptimmune 'ready for primetime' as it prepares to launch T cell therapy for sarcoma, CEO Adrian Rawcliffe says

Philadelphia’s Adaptimmune isn’t new to the biotech scene, but CEO Adrian Rawcliffe says the company is finally “ready for primetime.”

Ahead of a Thursday …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Adap­ti­m­mune 'ready for prime­time' as it pre­pares to launch T cell ther­a­py for sar­co­ma, CEO Adri­an Raw­cliffe says